Regeneron Stock Performance

REGN
 Stock
  

USD 628.71  4.81  0.77%   

The company holds a Beta of 0.8015, which implies possible diversification benefits within a given portfolio. Let's try to break down what Regeneron's beta means in this case. As returns on the market increase, Regeneron Pharmaceuticals returns are expected to increase less than the market. However, during the bear market, the loss on holding Regeneron Pharmaceuticals will be expected to be smaller as well. Even though it is essential to pay attention to Regeneron Pharmaceuticals current trending patterns, it is always good to be careful when utilizing equity existing price patterns. Our philosophy towards forecasting any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Regeneron Pharmaceuticals exposes twenty-eight different technical indicators, which can help you to evaluate its performance. Regeneron Pharmaceuticals has an expected return of -0.044%. Please be advised to check Regeneron Pharmaceuticals downside variance, and the relationship between the sortino ratio and accumulation distribution to decide if Regeneron Pharmaceuticals performance from the past will be repeated at some point in the near future.
  
Regeneron Performance
0 of 100
Over the last 90 days Regeneron Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent technical and fundamental indicators, Regeneron Pharmaceuticals is not utilizing all of its potentials. The latest stock price mess, may contribute to short-term losses for the institutional investors. ...more

Regeneron Price Channel

Quick Ratio3.95
Fifty Two Week Low538.01
Target High Price790.00
Fifty Two Week High747.42
Target Low Price536.00

Regeneron Pharmaceuticals Relative Risk vs. Return Landscape

If you would invest  65,501  in Regeneron Pharmaceuticals on May 16, 2022 and sell it today you would lose (2,630)  from holding Regeneron Pharmaceuticals or give up 4.02% of portfolio value over 90 days. Regeneron Pharmaceuticals is currently does not generate positive expected returns and assumes 2.0138% risk (volatility on return distribution) over the 90 days horizon. In different words, 17% of stocks are less volatile than Regeneron, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Daily Expected Return (%)  
       Risk (%)  
Given the investment horizon of 90 days Regeneron Pharmaceuticals is expected to under-perform the market. In addition to that, the company is 1.61 times more volatile than its market benchmark. It trades about -0.02 of its total potential returns per unit of risk. The DOW is currently generating roughly 0.06 per unit of volatility.

Regeneron Pharmaceuticals Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Regeneron Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Regeneron Pharmaceuticals, and traders can use it to determine the average amount a Regeneron Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.0219

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative ReturnsREGN
Estimated Market Risk
 2.01
  actual daily
 
 17 %
of total potential
 
1717
Expected Return
 -0.04
  actual daily
 
 0 %
of total potential
 
00
Risk-Adjusted Return
 -0.02
  actual daily
 
 0 %
of total potential
 
00
Based on monthly moving average Regeneron Pharmaceuticals is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Regeneron Pharmaceuticals by adding it to a well-diversified portfolio.

About Regeneron Pharmaceuticals Performance

To evaluate Regeneron Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Regeneron Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Regeneron Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Regeneron Pharmaceuticals stock market performance in a much more refined way. At Macroaxis, we take it even further. The Macroaxis performance score is an integer between 0 and 100 that represents Regeneron's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Return on Investment 51.91  56.00 
Return on Average Assets 37.91  40.91 
Return on Average Equity 54.21  58.49 
Return on Invested Capital 0.23  0.25 
Return on Sales 0.25  0.27 
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10492 people.

Things to note about Regeneron Pharmaceuticals

Checking the ongoing alerts about Regeneron Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Regeneron Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Regeneron Pharmaceuticals Alerts

Equity Alerts and Improvement Suggestions

Regeneron Pharmaceuticals generated a negative expected return over the last 90 days
Regeneron Pharmaceuticals is unlikely to experience financial distress in the next 2 years
Regeneron Pharmaceuticals has a strong financial position based on the latest SEC filings
Over 88.0% of the company shares are owned by institutional investors
Latest headline from MacroaxisInsider: Exercise or conversion by Neil Stahl of 95000 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Additionally, take a look at Your Equity Center. Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Complementary Tools for Regeneron Stock analysis

When running Regeneron Pharmaceuticals price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
-0.73
Market Capitalization
68.5 B
Quarterly Revenue Growth YOY
-0.44
Return On Assets
0.18
Return On Equity
0.32
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Regeneron Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.